Ari David Baron

24.4k total citations · 4 hit papers
71 papers, 12.9k citations indexed

About

Ari David Baron is a scholar working on Oncology, Hepatology and Cancer Research. According to data from OpenAlex, Ari David Baron has authored 71 papers receiving a total of 12.9k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 40 papers in Hepatology and 17 papers in Cancer Research. Recurrent topics in Ari David Baron's work include Hepatocellular Carcinoma Treatment and Prognosis (38 papers), Cancer Immunotherapy and Biomarkers (14 papers) and Colorectal Cancer Treatments and Studies (13 papers). Ari David Baron is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (38 papers), Cancer Immunotherapy and Biomarkers (14 papers) and Colorectal Cancer Treatments and Studies (13 papers). Ari David Baron collaborates with scholars based in United States, France and United Kingdom. Ari David Baron's co-authors include Thomas H. Cartwright, Herbert I. Hurwitz, Fairooz F. Kabbinavar, Eric Holmgren, Gwen Fyfe, Louis Fehrenbacher, W. Heim, John D. Hainsworth, Napoleone Ferrara and William Novotny and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Annals of Internal Medicine.

In The Last Decade

Ari David Baron

70 papers receiving 12.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

2004 8.4k citations Ari David Baron et al. profile →
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

2017 1.2k citations Padmanee Sharma, Margitta Retz et al. The Lancet Oncology profile →
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

2020 850 citations Richard S. Finn, Masafumi Ikeda et al. Journal of Clinical Oncology profile →
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

2015 634 citations Andrew X. Zhu, Joon Oh Park et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Ari David Baron

Since Specialization

Citations

This map shows the geographic impact of Ari David Baron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ari David Baron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ari David Baron more than expected).

Fields of papers citing papers by Ari David Baron

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ari David Baron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ari David Baron. The network helps show where Ari David Baron may publish in the future.

Co-authorship network of co-authors of Ari David Baron

This figure shows the co-authorship network connecting the top 25 collaborators of Ari David Baron. A scholar is included among the top collaborators of Ari David Baron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ari David Baron. Ari David Baron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Nivolumab plus ipilimumab (N+I) in patients (pts) with pancreatic cancer (PC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. 2025 ·Journal of Clinical Oncology ·Peter J. Hosein, Michael Rothe, Elizabeth Garrett‐Mayer, Ari David Baron, Timothy Lewis Cannon, Evan Pisick, (unknown), Kathryn F. Mileham, (unknown), Marina Frimer, Philip J. Gold, Kelsey Klute, (unknown), Vaibhav Sahai, Davendra Sohal, Sachdev Thomas, (unknown), (unknown), Susan Halabi, Richard L. Schilsky	1
2	ctDNA analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) or sorafenib (SOR) as 1L therapy. 2024 ·Journal of Clinical Oncology ·T.R. Jeffry Evans, Masatoshi Kudo, Ann‐Lii Cheng, Lucjan Wyrwicz, Roger K.C. Ngan, Jean-Frédéric Blanc, Ari David Baron, Arndt Vogel, Masafumi Ikeda, Fabio Piscaglia, Shukui Qin, Taisuke Hoshi, (unknown), Yasuhiro Funahashi, Chinyere E. Okpara, Koji Sagane, Dongyuan Xing, Yukinori Minoshima, Richard S. Finn	1
3	A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116 2023 ·Liver Cancer ·Masatoshi Kudo, Richard S. Finn, Masafumi Ikeda, Max W. Sung, Ari David Baron, Takuji Okusaka, Masahiro Kobayashi, Hiromitsu Kumada, Shuichi Kaneko, Marc Pracht, Tim Meyer, (unknown), Kenichi Saito, Kalgi Mody, (unknown), Leonid Dubrovsky, Josep M. Llovet	3
4	Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial 2022 ·European Journal of Cancer ·Nick Freemantle, Patrick Mollon, Tim Meyer, Ann‐Lii Cheng, Anthony B. El-Khoueiry, Robin Kate Kelley, Ari David Baron, Fawzi Benzaghou, Milan Mangeshkar, Ghassan K. Abou‐Alfa	7
5	68P A phase Ib study of lenvatinib + pembrolizumab (LEN + PEMBRO) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 116 follow-up analysis 2021 ·Annals of Oncology ·Masatoshi Kudo, Richard S. Finn, Masafumi Ikeda, Andrew X. Zhu, Max W. Sung, Ari David Baron, Takuji Okusaka, Masahiro Kobayashi, H. Kumada, Shuichi Kaneko, Marc Pracht, (unknown), (unknown), Kenichi Saito, Kalgi Mody, Leonid Dubrovsky, Josep M. Llovet	1
6	Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial 2020 ·ESMO Open ·(unknown), Baek‐Yeol Ryoo, Philippe Merle, Joong‐Won Park, Luigi Bolondi, Stephen L. Chan, Ho-Yeong Lim, Ari David Baron, Francis Parnis, Jennifer J. Knox, Stéphane Cattan, Thomas Yau, Julie C. Lougheed, Steven Milwee, Anthony B. El-Khoueiry, Ann‐Lii Cheng, Tim Meyer, Ghassan K. Abou‐Alfa	61
7	Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer 2020 ·European Journal of Cancer ·Richard D. Kim, Shannon McDonough, Anthony B. El-Khoueiry, Tanios Bekaii‐Saab, Stacey Stein, Vaibhav Sahai, George P. Keogh, Edward Kim, Ari David Baron, Abby B. Siegel, Afsaneh Barzi, Katherine A. Guthrie, Milind Javle, Howard S. Höchster	26
8	Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH) 2019 ·Annals of Oncology ·Tim Meyer, Richard S. Finn, Masatoshi Kudo, Yoon‐Koo Kang, Chia‐Jui Yen, Peter R. Galle, Josep M. Llovet, Eric Assénat, Giovanni Brandi, Kenta Motomura, Takuji Okusaka, (unknown), Mark Karwal, Ari David Baron, Masafumi Ikeda, (unknown), (unknown), Ryan C. Widau, William R. Schelman, Andrew X. Zhu	3
9	CA209-9DX: Phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation 2018 ·Annals of Oncology ·(unknown), Mehmet Akce, José Luís Montero Álvarez, Éric Assenat, (unknown), Ari David Baron, Thomas Decaens, Alexandra Heurgué–Berlot, (unknown), Seung Woon Paik, Valerie Poulart, (unknown), (unknown), Nobuyuki Takemura, (unknown)	13
10	Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC) 2017 ·Annals of Oncology ·Richard S. Finn, Masatoshi Kudo, Ann‐Lii Cheng, Lucjan Wyrwicz, (unknown), (unknown), Ari David Baron, Arndt Vogel, Masafumi Ikeda, Fabio Piscaglia, Kwang‐Hyub Han, Shukui Qin, Yukinori Minoshima, Yasuhiro Funahashi, Min Ren, Ryo Dairiki, Perminder S. Sachdev, Toshiyuki Tamai, Corina E. Dutcus, T.R. Jeffry Evans	11
11	Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab 2017 ·Annals of Oncology ·(unknown), Charles S. Fuchs, Josep Tabernero, Atsushi Ohtsu, Andrew X. Zhu, Edward B. Garon, John R. Mackey, Luis Paz‐Ares, Ari David Baron, Takuji Okusaka, Takayuki Yoshino, Harry H. Yoon, Mayukh Das, D. Ferry, Y. Zhang, Yong Lin, (unknown), Andreas Sashegyi, Ian Chau	82
12	Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study 2016 ·Annals of Oncology ·Matt D. Galsky, Margitta Retz, Arlene O. Siefker‐Radtke, Ari David Baron, Andrea Necchi, Jens Bedke, Elizabeth R. Plimack, Daniel A. Vaena, Marc‐Oliver Grimm, Sergio Bracarda, (unknown), Sumanta K. Pal, Chikara Οhyama, Abdel Saci, Alexandre Lambert, (unknown), Alex Azrilevich, Padmanee Sharma	23
13	Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial breakdown → 2015 ·The Lancet Oncology ·Andrew X. Zhu, Joon Oh Park, Baek‐Yeol Ryoo, Chia-Jui Yen, Ronnie T. P. Poon, Davide Pastorelli, Jean-Frédéric Blanc, Hyun Cheol Chung, Ari David Baron, Túlio Pfiffer, Takuji Okusaka, Kateřina Kubáčková, Jörg Trojan, Javier Sastre, Ian Chau, Shao-Chun Chang, Paolo Abada, Ling Yang, Jonathan D. Schwartz, Masatoshi Kudo	634
14	An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors 2014 ·Cancer Chemotherapy and Pharmacology ·Pierre Maison‐Blanche, Shaker R. Dakhil, Ari David Baron, Sylvie Rottey, (unknown), Gedske Daugaard, Jean-Pascal Machiels, William R. Conkright, Sunil Sharma, Patricia M.M.B. Soetekouw, Jeffrey Yachnin, Lisa Sengeløv, Peter J. Van Veldhuizen, Sanjiv S. Agarwala, Dorothée Sémiond, Mustapha Chadjaa, Liji Shen, James L. Wade	1
15	Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer 2008 ·Annals of Oncology ·Arif Hussain, Robert S. DiPaola, Ari David Baron, Celestia S. Higano, N. Simon Tchekmedyian, A. Johri	44
16	A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma 2006 ·Lung Cancer ·Helen J. Ross, Lowell L. Hart, Paul Swanson, Mark U. Rarick, Robert A. Figlin, Andrew Jacobs, (unknown), Arthur Rosenberg, Ari David Baron, Laurie E. Grove, Michael Thorn, Dennis M. Miller, Jonathan G. Drachman, Charles M. Rudin	29
17	Epidemiological and quantitative study of GBV‐C infection in french polytransfused children 2004 ·Journal of Medical Virology ·Sandrine Castelain, Catherine François, Dorine Bonte, Ari David Baron, (unknown), Virginie Morel, Brigitte Pautard, Gilles Duverlie	9
18	Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma 1997 ·Cancer ·Eric J. Small, Ari David Baron, Robert Bok	71
19	Pseudomonas aeruginosa Bronchopulmonary Infection in Late Human Immunodeficiency Virus Disease 1993 ·American Review of Respiratory Disease ·Ari David Baron, Harry Hollander	56
20	The Sweet Syndrome during Therapy with Granulocyte Colony-stimulating Factor 1992 ·Annals of Internal Medicine ·John W. Park, Bhoomi Mehrotra, (unknown), Ari David Baron, (unknown)	103

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact